WCN26-4507 THERAPEUTIC POTENTIAL OF SILDENAFIL AND 5HT2B RECEPTOR ANTAGONIST IN PERITONEAL FIBROSIS THROUGH MODULATION OF FIBROBLAST METABOLISM AND DIFFERENTIATION

Read full text Summarise with VIRAT
Authors: Narayan Prasad, Harshit Singh, Saurabh Chaturvedi, Ravi Shankar Kushwaha, Santosh Kumar V, Vikas Agarwal, Vinita Agarwal
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Peritoneal fibrosis (PF), a major cause of technique failure in peritoneal dialysis (PD) patients, is driven by the excessive deposition of extracellular matrix (ECM) proteins, primarily mediated by the activation of fibroblasts into myofibroblasts. This activation is associated with a metabolic reprogramming from oxidative phosphorylation (OXPHOS) to glycolysis, particularly under profibrotic stimuli such as TGF-β1. This study investigated the anti-fibrotic potential of sildenafil, a phosphodiesterase-5 inhibitor, in modulating metabolism and inflammation in human peritoneal fibroblasts (HPFBs).

Fields of Study & Subjects

Dialysis and Renal Disease Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105888–105888
Publication date
25 March 2026
Language
EN